The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 27 | — | 20.1x | Below average | |
Growth | 5 | -52.3% | 5.6% | Below average | |
Quality | 7 | -110.2% | 7.6% | Below average | |
Safety | 27 | 0.3x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Lyell Immunopharma, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Lyell Immunopharma, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
LYEL stock has seen a slight and steady improvement in the average price target, with the consensus rising from 46 to 46.33 dollars over the past thirty days, an increase of 0.72%. This adjustment, though small, reflects stability in the positive outlook among following analysts, with a significant gap between the current price (12.57) and the minimum target (45), suggesting either excessive optimism or expectations of substantial future growth.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.